Carlyle and SK Capital Partners are buying beleaguered gene therapy biotech Bluebird Bio for about $29 million.

12 years after going public, beleaguered gene therapy company bluebird bio will be sold to private equity groups Carlyle and ...

Bluebird bio (BLUE) shares continued their downward descent Monday following news that the company plans to be taken private through a deal valued at up to $96M. Read more here.

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed ...

Wells Fargo analyst Yanan Zhu lowered the firm’s price target on Bluebird Bio (BLUE) to $5 from $40 and keeps an Equal Weight rating on the ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

明星药企陨落的悲剧正在发生。 2月21日，基因治疗领域的昔日明星蓝鸟生物（bluebird bio）宣布被私募巨头凯雷集团（Carlyle Group）和SK Capital以总价约1亿美元收购。根据协议，每股股东将获得3美元现金，若公司现有疗法在2027年底前销售额达到6亿美元，还可额外获得6.84美元“奖金”，总价最高近10美元/股。交易需满足多数股东投标、监管批准等条件，预计2025年上半年 ...

Last week’s significant news was dominated by licensing deals and mergers and acquisitions. US biotech giant Biogen entered ...

本文来自微信公众号：氨基观察，作者：郑晓，题图来自：Bluebird Bio 创新药企创业，成功是小概率事件，失败、消失是最常见的结局。 过去 20 多年的 biotech ...

NSM Insurance Group announced it has signed a definitive agreement to sell its U.S. commercial insurance division to New Mountain Capital, a ...

Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders ...

Patrizia Cavazzoni, formerly the top regulator of the drug division of the FDA, will join Pfizer as chief medical officer.